Table 1

Data on biochemical markers of ovarian reserve from randomised controlled studies investigating GnRHa cotreatment during gonadotoxic treatment in women with cancer

Type of cancerAuthor, yearOvarian marker studiedProtective effect (yes/no)Study results
Hodgkin lymphomaNitzschke et al, 201022AMH and inhibinNoFollow-up 2.7 years.
No difference between the groups.
Hodgkin lymphomaBehringer et al, 201017AMH and inhibinNoFollow-up 18 months.
Ovarian markers reduced in both arms.
Breast cancerMunster et al, 201021InhibinNoFollow-up 18 months. Two pregnancies in the control group.
Breast cancerGerber et al, 201120AMH and inhibinNoFollow-up 6 months.
Ovarian markers reduced in both arms.
Breast cancerElgindy et al, 201119AMHNoFollow-up 12 months.
Ovarian marker reduced in both groups.
Breast cancerDel Mastro et al, 201110No sensitive ovarian markers investigated.
FSH randomly assessed		YesFollow up 12 months. Menstruation resumption reported but subjectively in an unblinded study.
Breast cancerMoore et al, 2015 and 2019 11 12No sensitive ovarian markers investigated, FSH and inhibin measured but results not reportedYesStudy originally powered for 416 patients. Number reported by ITT 218 with only 135 with complete data after 2 years follow up. Menstruation resumption reported but in an unblinded study. Women attempted and achieved pregnancy to a higher degree in the group that received GnRHa.
Breast cancerLeonard et al, 201716AMH and FSHYesFollow up 24 months. Significant reduction of amenorrhoea. No significant difference in AMH.
LymphomaDemeestere et al, 201618AMH and inhibinNoFollow-up 7 years.
No effect on AMH or in pregnancies.

  • AMH, anti-Müllerian hormone; FSH, follicle stimulating hormone; GnRHa, gonadotropin-releasing hormone agonists; ITT, intention-to-treat.